NCT00161135

Brief Summary

This study aims to investigate the overlap and differences between autism and MCDD as neuropsychiatric childhood disorders. MRI scans are acquired from subjects with autism, subjects with a diagnosis of MCDD and typically developing controls. Volumetric measure of various brain regions are compared between groups. We hypothesize that subjects with autism will have larger brains than controls, whereas subjects with MCDD will have smaller brains.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 1999

Completed
6.7 years until next milestone

First Submitted

Initial submission to the registry

September 8, 2005

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 12, 2005

Completed
Last Updated

April 20, 2007

Status Verified

April 1, 2007

First QC Date

September 8, 2005

Last Update Submit

April 19, 2007

Conditions

AutismDevelopmental Disabilities

Keywords

MRIPDD-NOS, MCDD

Eligibility Criteria

Age7 Years - 24 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Diagnosis of autism according to ADI-interview or diagnosis of MCDD according to the MCDD-checklist or no psychiatric diagnosis (controls)

You may not qualify if:

  • Some medical and neurological diseases (if there are influences on the brain structures)
  • Alcohol or drug abuse
  • IQ \< 70
  • Focal abnormalities on the MRI scan

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dept. of Child and Adolescent Psychiatry, UMC Utrecht

Utrecht, 3584CX, Netherlands

Location

Related Publications (2)

  • Palmen SJ, Hulshoff Pol HE, Kemner C, Schnack HG, Durston S, Lahuis BE, Kahn RS, Van Engeland H. Increased gray-matter volume in medication-naive high-functioning children with autism spectrum disorder. Psychol Med. 2005 Apr;35(4):561-70. doi: 10.1017/s0033291704003496.

    PMID: 15856726RESULT

  • Palmen SJ, Hulshoff Pol HE, Kemner C, Schnack HG, Janssen J, Kahn RS, van Engeland H. Larger brains in medication naive high-functioning subjects with pervasive developmental disorder. J Autism Dev Disord. 2004 Dec;34(6):603-13. doi: 10.1007/s10803-004-5282-2.

    PMID: 15679181RESULT

MeSH Terms

Conditions

Autistic DisorderDevelopmental Disabilities

Condition Hierarchy (Ancestors)

Autism Spectrum DisorderChild Development Disorders, PervasiveNeurodevelopmental DisordersMental Disorders

Study Officials

  • Bertine E Lahuis, M.D.

    Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht

    PRINCIPAL INVESTIGATOR

  • Sarah Durston, Ph.D.

    Rudolf Magnust Institute of Neuroscience, UMC Utrecht

    STUDY DIRECTOR

  • Herman van Engeland, M.D. Ph.D.

    Rudolf Magnus Institute of Neuroscience, UMC Utrecht

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
OTHER
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 8, 2005

First Posted

September 12, 2005

Study Start

January 1, 1999

Last Updated

April 20, 2007

Record last verified: 2007-04

Locations

NL(1)